Clinical Trials Browser

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

685 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

133 enrolled

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Clinical Trials

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Nasopharyngeal Carcinoma Post IMRT

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

NeoTurbo

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study

NPC-GTV

DIAMOND

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: an MRI Study

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

MABEL

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

GEMSTONE

"Xijiang Project" Screening Cohort for NPC

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone

Distribution of Bacteria in OME After Radiotherapy For NPC.

Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma